GT Biopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-11.67	-13.16	-7.6	-20.88	-58.01	-28.3	Upgrade
Other Amortization	-	-	-	-	-	0.32	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.06	Upgrade
Loss (Gain) From Sale of Investments	-0	-	-0.05	0.03	0.03	-	Upgrade
Stock-Based Compensation	0.13	0.23	2.2	7.65	33.93	0.27	Upgrade
Other Operating Activities	-0.22	-0.75	-5.23	-0.02	0.51	17.98	Upgrade
Change in Accounts Payable	0.99	0.94	1.96	-2.03	7.08	-0.84	Upgrade
Change in Other Net Operating Assets	-0.18	-0.16	-0.14	0.04	0.86	3.24	Upgrade
Operating Cash Flow	-10.94	-12.9	-8.85	-15.22	-15.61	-7.26	Upgrade
Investment in Securities	7.86	12.89	-2.01	12.15	-23.04	-	Upgrade
Investing Cash Flow	7.86	12.89	-2.01	12.15	-23.04	-	Upgrade
Short-Term Debt Issued	-	-	-	-	1.21	12.53	Upgrade
Total Debt Issued	-	-	-	-	1.21	12.53	Upgrade
Net Debt Issued (Repaid)	-	-	-	-	1.21	12.53	Upgrade
Issuance of Common Stock	3.59	2.98	6.27	-	41.11	-	Upgrade
Repurchase of Common Stock	-	-	-	-0.22	-	-	Upgrade
Financing Cash Flow	3.59	2.98	6.27	-0.22	42.32	12.53	Upgrade
Net Cash Flow	0.51	2.97	-4.59	-3.3	3.67	5.27	Upgrade
Free Cash Flow	-10.94	-12.9	-8.85	-15.22	-15.61	-7.26	Upgrade
Free Cash Flow Per Share	-5.12	-6.80	-6.57	-14.32	-16.63	-49.68	Upgrade
Cash Interest Paid	-	-	0.21	-	-	-	Upgrade
Levered Free Cash Flow	-9.17	-9.62	-4.68	-10.91	-0.82	-3.42	Upgrade
Unlevered Free Cash Flow	-9.17	-9.62	-4.55	-10.9	-0.38	-1.66	Upgrade
Change in Net Working Capital	1.15	0.87	-1.72	5.26	-1.64	-2.29	Upgrade

Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q